摘要
目的:评价奈达铂和顺铂在宫颈癌同步放化疗(CCRT)中的效果和毒副反应。方法:68例宫颈癌初治患者,随机分为两组,放疗采用盆腔外照射+高剂量率腔内后装放疗,同期化疗与放疗同时开始,每周1次,共6次。奈达铂组同步给予奈达铂40mg/m2,每周1次,化疗6周;顺铂组同步给予顺铂40mg/m2,每周1次,化疗6周。观察两组的治疗效果和毒副反应,并进行比较。结果:所有患者完成了CCRT,奈达铂组与顺铂组的1、2、3年生存率分别为91.2%、82.4%、76.5%和85.3%、73.5%、70.6%(P>0.05);1、2、3年无瘤生存率分别为88.2%、73.5%、64.7%和82.3%、64.7%、61.8%(P>0.05)。两组Ⅰ、Ⅱ级厌食反应分别为17.6%(6/34)和35.3%(12/34)(P<0.05),Ⅰ、Ⅱ级恶心呕吐反应分别为20.6%(7/34)和55.9%(19/34)(P<0.05);血红蛋白下降两组分别为17.6%(6/34)和35.3%(12/34)(P<0.05);Ⅰ、Ⅱ级肾脏毒性分别为5.9%(2/34)和32.4%(11/34)(P<0.05);Ⅰ、Ⅱ级血小板减少分别为38.2%(13/34)和17.6%(6/34)(P<0.05)。结论:奈达铂可应用于宫颈癌CCRT治疗,其胃肠反应和肾脏毒性低于顺铂,总生存率和无瘤生存率与顺铂相同,但有提高趋势,值得扩大病例数做进一步研究。
Objective：To evaluate the effect and side-effect of Nedaplatin and cisplatin（DDP） in concur-rent chemoradiotherapy（CCRT） treatment of cervical cancer.Methods：68 first treated cervical cancer patients were randomly classified to two groups,Nedaplatin group and DDP group. Radiotherapy in two groups was the same,which used external radiation with 3 dimensional conformal radiation therapy technic（3-DCRT） and high dose rate intracavitary therapy.The radiation and CCRT started at the same time,and the frequence was once every week for 6 weeks. The Nedaplatin group was given Nedaplatin 40 mg/m2,ivgtt,weekly,for 6 weeks. DDP group was given DDP 40 mg/m2,ivgtt,weekly,for 6 weeks. The effects and side-effects of treatment in two groups were observed and compared.Results：All patients had finished CCRT treatment and followed up. Overall survival rate at 1,2,3 years in Nedaplatin group and DDP group were 91.2%、82.4%、76.5% and 85.3%、73.5%、70.6%（P0.05） respectively. Disease free survival rate at 1,2,3 years in Nedaplatin group and DDP group were 88.2%、73.5%、64.7% and 82.3%、64.7%、61.8%（P0.05） respectively. Incidence of grand Ⅰ and grand Ⅱ anorexia was 17.6%（6/34） and 35.3%（12/34）（P0.05） ,incidence of grade Ⅰ and Ⅱ nausea and vomiting reaction were 20.6%（7/34） and 55.9%（19/34）（P0.05） . The descending percentage of hemoglobin in two groups were 17.6%（6/34） and 35.3%（12/34） respectively（P0.05） . Incidence of grandⅠand grand Ⅱ nephrotoxicity were 5.9%（2/34） and 32.3%（11/34） （P0.05） . Incidence of grandⅠand grand Ⅱ thrombocytopenia were 38.2%（13/34） and 17.6%（6/34）（P0.05） .Conclusions：Nedaplatin can be used in CCRT in cervical cancer. The side effects of Nedaplatin including gastrointestinal reaction and renal toxicity are lower than that of cisplatin. The total survival rate and disease free survival rate are the same,but tends to elevate in Nedaplatin,which is worth to give further study by enlarging the sample size.
出处
《实用妇产科杂志》
CAS
CSCD
北大核心
2011年第10期771-774,共4页
Journal of Practical Obstetrics and Gynecology
关键词
宫颈癌
同步放化疗
顺铂
奈达铂
Cervical cancer
Concurrent chemoradiotherapy
Cisplatin
Nedaplatin
